GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹21 Cr | ₹16 Cr | ₹22 Cr | ₹13 Cr | ₹75 Cr |
What is the latest Contingent Liabilities ratio of GLAND PHARMA ?
| Year | Contingent Liabilities |
|---|---|
| Mar2025 | ₹21 Cr |
| Mar2024 | ₹16 Cr |
| Mar2023 | ₹22 Cr |
| Mar2022 | ₹13 Cr |
| Mar2021 | ₹75 Cr |
How is Contingent Liabilities of GLAND PHARMA Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹21 Cr | 37.24 | |
| Mar2024 | ₹16 Cr | -29.41 | |
| Mar2023 | ₹22 Cr | 72.94 | |
| Mar2022 | ₹13 Cr | -82.91 | |
| Mar2021 | ₹75 Cr | - | |
Compare Contingent Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹29,583.2 Cr | -0.3% | -2.3% | 19.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹420,531.0 Cr | 1.3% | 8.9% | 6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹169,989.0 Cr | 2.4% | 6% | 12.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹147,936.0 Cr | -0.6% | 9.4% | 44.1% | Stock Analytics | |
| CIPLA | ₹109,200.0 Cr | 1.9% | 2% | -8.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹108,057.0 Cr | -0.4% | 9.5% | 10.5% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | -0.3% |
-2.3% |
19.5% |
| SENSEX | -3.7% |
-2.5% |
6.5% |
You may also like the below Video Courses